Surgery Partners (SGRY) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGRY shares.
View SGRY analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 12 month price objectives for Surgery Partners' stock. Their SGRY share price forecasts range from $35.00 to $56.00. On average, they expect the company's stock price to reach $44.09 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price.
View analysts price targets for SGRY or view top-rated stocks among Wall Street analysts.

Surgery Partners' stock was trading at $27.86 at the beginning of the year. Since then, SGRY shares have increased by 39.4% and is now trading at $38.85.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SGRY earnings forecast.

Surgery Partners, Inc. (NASDAQ:SGRY) issued its quarterly earnings results on Monday, May, 1st. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.09. The business had revenue of $666.20 million for the quarter, compared to analyst estimates of $644.16 million. Surgery Partners had a negative net margin of 3.51% and a positive trailing twelve-month return on equity of 0.59%.

ETFs with the largest weight of Surgery Partners (NASDAQ:SGRY) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), iShares U.S. Healthcare Providers ETF (IHF), First Trust Mid Cap Growth AlphaDEX Fund (FNY), JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE), Inspire Small/Mid Cap ETF (ISMD), Fidelity MSCI Health Care Index ETF (FHLC), Vanguard Health Care ETF (VHT) and Fidelity Blue Chip Growth ETF (FBCG).

7 employees have rated Surgery Partners Chief Executive Officer Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Glu Mobile (GLUU), Ocular Therapeutix (OCUL), Sangamo Therapeutics (SGMO), Xilinx (XLNX), Allena Pharmaceuticals (ALNA), Editas Medicine (EDIT) and Maxar Technologies (MAXR).

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Surgery Partners' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.95%), Wellington Management Group LLP (5.49%), Clearbridge Investments LLC (4.40%), BlackRock Inc. (3.01%), State Street Corp (0.99%) and Geode Capital Management LLC (0.96%). Insiders that own company stock include Anthony Taparo, Bradley R Owens, Brent Turner, Danielle Burkhalter, David T Doherty, George Goodwin, Jason Eric Evans, Jennifer Baldock, Laura L Brocklehurst, Laura L Brocklehurst, Marissa Brittenham, Teresa Deluca, Thomas F Cowhey and Wayne S Deveydt.
View institutional ownership trends.

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGRY stock can currently be purchased for approximately $38.85.

Surgery Partners (NASDAQ:SGRY) has a market capitalization of $4.91 billion and generates $2.54 billion in revenue each year. The company earns $-54,600,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

The company employs 12,200 workers across the globe.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The official website for the company is www.surgerypartners.com. The company can be reached via phone at (615) 234-5900, via email at ir@surgerypartners.com, or via fax at 615-234-5998.